Craig H Syrop1, Sarah A Wernimont1, Diedre K Fleener1, Joseph M Kardos2, Linda M Rubenstein3, Janet I Andrews1. 1. Department of Obstetrics & Gynecology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA. 2. University of Iowa Health Care, Operational Analysis and Business Intelligence Unit, University of Iowa Health Care, Iowa City, Iowa, USA. 3. Department of Epidemiology, University of Iowa College of Public Health, Iowa City, Iowa, USA.
Abstract
Objective: We sought to improve perinatal glycemic control and downstream neonatal outcomes through redesigned ambulatory management for women with insulin-requiring diabetes in pregnancy. Methods: To address gaps in perinatal glycemic management of women with insulin-requiring diabetes in pregnancy, redesigned care delivery (RCD) utilized integrated practice unit and minimally disruptive medicine concepts with incorporation of cellular-enabled glucose monitoring. Primary outcomes of RCD (N = 129) included hemoglobin A1c ([HbA1c], within RCD cohort), and gestational age (GA) at delivery, neonatal intensive care (NICU) admission, and NICU length of stay (LOS) compared with a preredesign care cohort (Pre-RCD; N = 122). Secondary outcomes included facility, payer reimbursement, and program costs. Generalized linear models assessed continuous variables while logistic regression methods assessed categorical outcomes. Results: Utilizing RCD, 92% of women with an initial HbA1c <6.5% maintained glycemic control until delivery, and 67.2% with an initial HbA1c ≥6.5% achieved delivery levels <6.5%. NICU admissions and GA-adjusted LOS decreased significantly [Pre-RCD vs. RCD: NICU admissions, 41.0% vs. 27.3%, p < 0.024; NICU LOS (95% confidence interval [CI]), 21.9 (17.1-26.6) vs. 14.6 (9.1-20.1), p = 0.045]. Every 10 days of redesigned management decreased mean NICU LOS by 1 day. Mean payer neonatal reimbursements decreased over $18,000 per delivery (p = 0.08) compared with implementation costs of $1,942 per delivery. Conclusion: Redesigned perinatal diabetes care with remote glucose monitoring demonstrated improved outcomes and value through downstream neonatal outcomes and lower payer costs. Therefore, subsequent dissemination and sustainability of similar programs' improved outcomes will likely require payer support.
Objective: We sought to improve perinatal glycemic control and downstream neonatal outcomes through redesigned ambulatory management for women with insulin-requiring diabetes in pregnancy. Methods: To address gaps in perinatal glycemic management of women with insulin-requiring diabetes in pregnancy, redesigned care delivery (RCD) utilized integrated practice unit and minimally disruptive medicine concepts with incorporation of cellular-enabled glucose monitoring. Primary outcomes of RCD (N = 129) included hemoglobin A1c ([HbA1c], within RCD cohort), and gestational age (GA) at delivery, neonatal intensive care (NICU) admission, and NICU length of stay (LOS) compared with a preredesign care cohort (Pre-RCD; N = 122). Secondary outcomes included facility, payer reimbursement, and program costs. Generalized linear models assessed continuous variables while logistic regression methods assessed categorical outcomes. Results: Utilizing RCD, 92% of women with an initial HbA1c <6.5% maintained glycemic control until delivery, and 67.2% with an initial HbA1c ≥6.5% achieved delivery levels <6.5%. NICU admissions and GA-adjusted LOS decreased significantly [Pre-RCD vs. RCD: NICU admissions, 41.0% vs. 27.3%, p < 0.024; NICU LOS (95% confidence interval [CI]), 21.9 (17.1-26.6) vs. 14.6 (9.1-20.1), p = 0.045]. Every 10 days of redesigned management decreased mean NICU LOS by 1 day. Mean payer neonatal reimbursements decreased over $18,000 per delivery (p = 0.08) compared with implementation costs of $1,942 per delivery. Conclusion: Redesigned perinatal diabetes care with remote glucose monitoring demonstrated improved outcomes and value through downstream neonatal outcomes and lower payer costs. Therefore, subsequent dissemination and sustainability of similar programs' improved outcomes will likely require payer support.
Entities:
Keywords:
health care delivery; integrated practice unit; perinatal diabetes outcomes; remote monitoring
Authors: Lene R Nielsen; Pia Ekbom; Peter Damm; Charlotte Glümer; Merete M Frandsen; Dorte M Jensen; Elisabeth R Mathiesen Journal: Diabetes Care Date: 2004-05 Impact factor: 19.112
Authors: Jane E Hirst; Lucy Mackillop; Lise Loerup; Dev A Kevat; Katy Bartlett; Oliver Gibson; Yvonne Kenworthy; Jonathan C Levy; Lionel Tarassenko; Andrew Farmer Journal: J Diabetes Sci Technol Date: 2014-10-30
Authors: James T Fitzgerald; Martha M Funnell; Robert M Anderson; Robin Nwankwo; R Brent Stansfield; Grecthen A Piatt Journal: Diabetes Educ Date: 2016-01-14 Impact factor: 2.140
Authors: Wai-Kit Ming; Lucy H Mackillop; Andrew J Farmer; Lise Loerup; Katy Bartlett; Jonathan C Levy; Lionel Tarassenko; Carmelo Velardo; Yvonne Kenworthy; Jane E Hirst Journal: J Med Internet Res Date: 2016-11-09 Impact factor: 5.428
Authors: Timothy M Dall; Wenya Yang; Karin Gillespie; Michelle Mocarski; Erin Byrne; Inna Cintina; Kaleigh Beronja; April P Semilla; William Iacobucci; Paul F Hogan Journal: Diabetes Care Date: 2019-04-02 Impact factor: 19.112
Authors: Denice S Feig; Lois E Donovan; Rosa Corcoy; Kellie E Murphy; Stephanie A Amiel; Katharine F Hunt; Elizabeth Asztalos; Jon F R Barrett; J Johanna Sanchez; Alberto de Leiva; Moshe Hod; Lois Jovanovic; Erin Keely; Ruth McManus; Eileen K Hutton; Claire L Meek; Zoe A Stewart; Tim Wysocki; Robert O'Brien; Katrina Ruedy; Craig Kollman; George Tomlinson; Helen R Murphy Journal: Lancet Date: 2017-09-15 Impact factor: 79.321
Authors: Lucy Mackillop; Jane Elizabeth Hirst; Katy Jane Bartlett; Jacqueline Susan Birks; Lei Clifton; Andrew J Farmer; Oliver Gibson; Yvonne Kenworthy; Jonathan Cummings Levy; Lise Loerup; Oliver Rivero-Arias; Wai-Kit Ming; Carmelo Velardo; Lionel Tarassenko Journal: JMIR Mhealth Uhealth Date: 2018-03-20 Impact factor: 4.773